PSA testing: Molecular technologies and men's experience of prostate cancer survivorship

Health, Risk and Society

Volumn 13, Issue 2, 2011, Pages 183-198

  Bell, Kirsten ^a   Kazanjian, Arminee ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cancer screening; Cancer survivorship; Perceived risk; Prostate cancer; Risk assessment

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SURVIVAL; CANCER SURVIVOR; PROSTATE CANCER;

EID: 79953692984     PISSN: 13698575     EISSN: 14698331     Source Type: Journal    
DOI: 10.1080/13698575.2011.556187     Document Type: Article

References (62)

1. Agalliu, I., et al., 2009. Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations. Clinical Cancer Research, 15 (3), 1112-1120.
2. Andriole, G.L., et al., 2009. Mortality results from a randomized prostate-cancer screening trial. New England Journal of Medicine, 360 (13), 1310-1319.
3. Armstrong, D., 1995. The rise of surveillance medicine. Sociology of Health and Illness, 17 (3), 393-404.
4. Aronowitz, R.A., 2009. The converged experience of risk and disease. Milbank Quarterly, 87 (2), 417-442.
5. Aslan, G., et al., 2005. The value of PSA, free-to-total PSA Ratio and PSA density in the prediction of pathologic stage for clinically localized prostate cancer. International Urology and Nephrology, 37 (3), 511-514.
6. Avis, M., et al., 2008. Ethnicity and participation in cancer self-help groups. Psycho-oncology, 17 (9),940-947. DOI:10.1002/pon.1284.
7. Balshem, M., 1991. Cancer, control, and causality: Talking about cancer in a working-class community. American Ethnologist, 18 (1), 152-172.
8. Beaulac, J.A., Fry, R.N., and Onysko, J., 2006. Lifetime and recent prostate specific antigen (PSA) screening of men for prostate cancer in Canada. Canadian Journal of Public Health, 97 (3),171-176.
9. Beck, U., 1992. Risk society: Towards a new modernity. New Dehli: Sage.
10. Bottorff, J.L., et al., 2008. Women and prostate cancer support groups: The gender connect? Social Science and Medicine, 66 (5), 1217-1227.
11. Breslow, N., et al., 2006. Latent carcinoma of prostate at autopsy in seven areas. Collaborative study organized by the International Agency for Research on Cancer, Lyons, France. International Journal of Cancer, 20 (5), 680-688.
12. CCS/NCIC, 2007. Canadian cancer statistics 2007. Toronto, Canada: Canadian Cancer Society.
13. Chapple, A. and Ziebland, S., 2002. Prostate cancer: Embodied experience and perceptions of masculinity. Sociology of Health and Illness, 24 (6), 820-841.
14. Chapple, A., et al., 2002a. Why men with prostate cancer want wider access to prostate specific antigen testing: A qualitative study. British Medical Journal, 325, 1-5.
15. Chapple, A., et al., 2002b. Is 'watchful waiting' a real choice for men with prostate cancer? A qualitative study. BJU International, 90, 257-264.
16. Clark, A.E., et al., 2003. Biomedicalization: Technoscientific transformations of health, illness, and US biomedicine. American Sociological Review, 68 (2), 161-194.
17. Comaroff, J. and Maguire, P., 1981. Ambiguity and the search for meaning: Childhood leukemia in the modern clinical context. Social Science and Medicine, 15B, 115-123.
18. D'Amico, A.V., et al., 2004. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. Journal of Urology, 172 (5 pt 2), S42-S46.
19. Davison, B.J., So, A.I., and Goldenberg, S.L., 2007. Quality of life, sexual function and decisional regret at 1 year after surgical treatment for localized prostate cancer. BJU International, 100, 780-785.
20. Donovan, J., et al., 2003. Prostate testing for cancer and treatment feasibility study. Health Technology Assessment, 7, 1-88.
21. Eton, D.T. and Lepore, S.J., 2002. Prostate cancer and health-related quality of life: A review of the literature. Psycho-oncology, 11, 307-326.
22. Fayerman, P., 2009. Prostate cancer 'likely cure' prompts BC debate. Vancouver sun. Available from: http://www.vancouversun.com/health/Prostatethcancerthlikelythcurethpromptsth debate/1250043/story.html [Accessed 2 September 2009].
23. Frank, A., 1991. At the will of the body: Reflections on illness. Boston: Houghton Mifflin.
24. Giddens, A., 1999. Risk and responsibility. Modern Law Review, 62 (1), 1-10.
25. Gray, R., et al., 1996. Breast cancer and prostate cancer self-help groups: Reflections on differences. Psycho-oncology, 5, 137-142.
26. Gray, R.E., et al., 2002. Hegemonic masculinity and the experience of prostate cancer: A narrative approach. Journal of Aging and Identity, 7 (1), 43-62.
27. Green, C.J., Kazanjian, A., and Gallagher, R., 2000. Prostate cancer services utilization pre- and post-PSA: A population-based analysis. BC Office of Health Technology Assessment, University of British Columbia; Report No. BCOHTA 00:15C.
28. Hamilton, A.B., 1999. Psychological aspects of ovarian cancer. Cancer Investigation, 17 (5), 335-341.
29. Howell, D., Fitch, M.I., and Deane, K.A., 2003. Women's experiences with recurrent ovarian cancer. Cancer Nursing, 26 (1), 10-17.
30. IM/NRC, 2005. From cancer patient to cancer survivor: Lost in transition. Washington, DC: National Academies Press.
31. Jones, J.S., Follis, H.W., and Johnson, J.R., 2009. Probability of finding T1a and T1b (incidental) prostate cancer during TURP has decreased in the PSA era. Prostate Cancer and Prostatic Diseases, 12, 57-60.
32. Khan, F.A., et al., 2005. PSA recurrence folling radical prostatectomy is comparable for all age groups in the UK. Prostate Cancer and Prostatic Disease, 8, 158-162.
33. Lin, K., et al., 2008. Benefits and harms of prostate-specific antigen screening for prostate cancer: An evidence update for the US Preventive Services Task Force. Annals of Internal Medicine, 149 (3), 192-199.
34. Lupton, D., 1999. Risk. New York: Routledge.
35. Mathews, H.F., 2000. Negotiating cultural consensus in a breast cancer self-help group. Medical Anthropology Quarterly, 14 (3), 394-413.
36. McLeod, D.G., 2005. The effective management of biochemical recurrence in patients with prostate cancer. Urology, 7 (Sup 5), S29-S36.
37. Moul, J.W., 2000. Prostate specific antigen only progression of prostate cancer. Journal of Urology, 163, 1632-1642.
38. Moul, J.W., 2006. Treatment of PSA only recurrence of prostate cancer after prior local therapy. Current Pharmaceutical Design, 12 (7), 785-798.
39. Moul, J.W., Banez, L.L., and Freedland, S.J., 2007. Rising PSA in nonmetastatic protaste cancer. Oncology, 21 (12), 1-4.
40. Oliffe, J., 2005. Constructions of masculinity following prostatectomy-induced impotence. Social Science and Medicine, 60, 2249-2259.
41. Oliffe, J.L., 2009. Health behaviors, prostate cancer, and masculinites. Men and Masculinities, 11 (3),346-366.
42. Oliffe, J.L., et al., 2008. How prostate cancer support groups do and do not survive: British Columbian perspectives. American Journal of Men's Health, 2 (2), 143-155.
43. Oliffe, J. and Thorne, S., 2007. Men, masculinities and prostate cancer: Australian and Canadian patient perspectives of communication with male physicians. Qualitative Health Research, 17 (2), 149-161.
44. Petersen, A. and Lupton, D., 1997. The new public health: Health and self in the age of risk. London: Sage.
45. Potosky, A.L., et al., 2000. Health outcomes after prostatectomy or radiotherapy for prostate cancer: Results from the Prostate Cancer Outcomes study. Journal of the National Cancer Institute, 92 (19), 1582-1592.
46. Pound, C.R. and Partin, A.W., 2000. What does prostate-specific antigen recurrence mean? Current Urology Reports, 1, 28-35.
47. Robertson, A., 2001. Biotechnology, political rationality and discourses on health risk. Health, 5 (3), 293-309.
48. Rose, N., 1993. Government, authority and expertise in advanced liberalism. Economy and Society, 22 (3), 283-299.
49. Rose, N.S., 1999. Governing the soul: The shaping of the private self. London: Free Association Books.
50. Rose, N.S., 2001. The politics of life itself. Theory, Culture and Society, 18 (6), 1-30.
51. Rose, N., 2007. The politics of life itself: Biomedicine, power, and subjectivity in the twenty-first century. Princeton: Princeton University Press.
52. Sanjek, R., 2000. Keeping ethnography alive in an urbanizing world. Human Organization, 59 (3),280-288.
53. Schroder, F.H., et al., 2009. Screening and prostate-cancer mortality in a randomized European study. New England Journal of Medicine, 360 (13), 1320-1328.
54. SEER, 2009. SEER stat fact sheets. Surveillance Epidemiology and End Results. Available from: http://seer.cancer.gov/statfacts/html/prost.html [Accessed 18 August 2009].
55. Sontag, S., 1990. Illness as metaphor and AIDS and its metaphors. New York: Picador.
56. Steginga, S.K., et al., 2001. The supportive care needs of men with prostate cancer (2000). Psycho-oncology, 10, 66-75.
57. Sulik, G.A., 2009. Managing biomedical uncertainty: The technoscientific illness identity. Sociology of Health and Illness, 30 (7), 1059-1076.
58. Ustun, C. and Ceber, E., 2004. Ethical issues for cancer screenings: Five countries-four types of cancer. Preventive Medicine, 39, 223-229.
59. Wall, D. and Kristjanson, L., 2005. Men, culture and hegemonic masculinity: Understanding the experience of prostate cancer. Nursing Inquiry, 12 (2), 87-97.
60. Watson, E., et al., 2006. Informed decision making and prostate specific antigen (PSA) testing for prostate cancer: A randomised controlled trial exploring the impact of a brief patient decision aid on men's knowledge, attitudes and intention to be tested. Patient Education and Counseling, 63, 367-379.
61. Whittington, R. and Vaughn, D.J., 2006. Prostate cancer. In: A.E. Chang et al., eds. Oncology: An evidence-based approach. New York: Springer, 826-843.
62. Zeliadt, S.B., et al., 2006. Why do men choose one treatment over another? A review of patient decision-making for localized prostate cancer. Cancer, 106 (9), 1865-1874.